Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employee options carry a $9.79 exercise price and vest over four years, subject to continued service.

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) granted stock options covering 55,500 shares to three new employees on November 2, 2026.

The Compensation Committee approved the employment inducement awards under the amended 2023 Inducement Option Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.79 per share, equal to the stock’s closing price on the grant date. Vesting runs over four years: 25% on the first anniversary of the applicable vesting commencement date, followed by monthly vesting of the balance over 36 months. Vesting requires continued service through each applicable date.

Positive

• None.

Negative

• Minor pointOptions covering 55,500 shares granted to three new employees at $9.79 per share create potential dilution.

News Explained

Kura has granted options to buy 55,500 shares; if exercise results in additional shares being issued, existing holders’ percentage ownership would decline absent offsets.

Key Figures

Inducement options: 55,500 shares Exercise price: $9.79 per share Vesting schedule: 4 years; 25% after 1 year, remainder monthly over 36 months

Inducement options

55,500 shares

Granted to three new employees

Exercise price

$9.79 per share

Equal to the November 2, 2026 closing price

Vesting schedule

4 years; 25% after 1 year, remainder monthly over 36 months

Subject to continued service

Historical Context

1 past event · Latest: Oct 02

1 event

1. Oct 02

   inducement grants

   24h Move

   +0.0%

   Granted employee options under the same plan, with a four-year vesting schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nonstatutory stock options, nasdaq listing rule 5635(c)(4)

2 terms

nonstatutory stock options financial

"inducement awards consisting of nonstatutory stock options"

A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 55,500 shares of common stock to three (3) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $9.79 per share, the closing price of the Company’s common stock on November 2, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did Kura Oncology grant to new employees?

Kura Oncology granted nonstatutory stock options to purchase 55,500 shares to three new employees on November 2, 2026. The exercise price is $9.79 per share, matching the closing stock price that day.

What is the vesting schedule for KURA’s November 2026 inducement options?

The options vest over four years, subject to continued service through the applicable vesting dates. Of the underlying shares, 25% vest on the first anniversary of the applicable vesting commencement date, with the balance vesting monthly over the following 36 months.